KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Sarepta Therapeutics (SRPT) over the last 15 years, with Q3 2025 value amounting to -$131.6 million.

  • Sarepta Therapeutics' Change in Receivables fell 27652.13% to -$131.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.8 million, marking a year-over-year decrease of 13353.1%. This contributed to the annual value of $201.7 million for FY2024, which is 859.56% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Change in Receivables of -$131.6 million as of Q3 2025, which was down 27652.13% from -$132.1 million recorded in Q2 2025.
  • In the past 5 years, Sarepta Therapeutics' Change in Receivables ranged from a high of $167.5 million in Q4 2024 and a low of -$132.1 million during Q2 2025
  • In the last 5 years, Sarepta Therapeutics' Change in Receivables had a median value of $13.1 million in 2022 and averaged $15.5 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Change in Receivables soared by 359880.6% in 2023, and later crashed by 60219.58% in 2025.
  • Sarepta Therapeutics' Change in Receivables (Quarter) stood at $3.2 million in 2021, then skyrocketed by 309.58% to $13.1 million in 2022, then soared by 521.02% to $81.5 million in 2023, then soared by 105.55% to $167.5 million in 2024, then tumbled by 178.56% to -$131.6 million in 2025.
  • Its Change in Receivables was -$131.6 million in Q3 2025, compared to -$132.1 million in Q2 2025 and $57.4 million in Q1 2025.